MedTrace Logo

Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer

NCT04338438 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2020-11-10

No results posted yet for this study

Summary

This is a single-arm, interventional study aimed to observe the efficacy and safety of Apatinib combined with S-1 for patients with advanced gastric cancer refractory to oxaliplatin plus capecitabine combination therapy

Conditions

Interventions

DRUG

Apatinib Mesylate tablets combined with S-1 capsules

Apatinib Mesylate tablets combined with S-1 capsules, p.o.

Sponsors & Collaborators

  • Beijing Friendship Hospital

    lead OTHER

Principal Investigators

  • Wei Deng, M.D. · Beijing Friendship Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-01
Primary Completion
2019-04-30
Completion
2020-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04338438 on ClinicalTrials.gov